OverviewALXN-MG-501: Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies
This is a long-term, multicenter, observational registry of participants with generalized myasthenia gravis (gMG) who are treated with Alexion complement C5 inhibition therapies (C5IT) prior to enrollment.Learn more at clinicaltrials.gov
- Participants with gMG who have received treatment with Alexion C5IT.
- Capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions.
- Participants must have myasthenia gravis historical data available to be enrolled in the Registry.
- Participants currently enrolled in an Alexion-sponsored interventional clinical study for treatment of gMG cannot be enrolled in the Alexion gMG Registry while enrolled/participating in the clinical study for gMG therapy.